Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 72Cytarabine 46fludarabine phosphate 45fludarabine 42Vincristine 29Filgrastim 27Peripheral Blood Stem Cell Transplantation 25Methotrexate 25Etoposide 24Dexamethasone 23Melphalan 21Rituximab 20Doxorubicin 19Clofarabine 19Tacrolimus 17Mycophenolic Acid 17Dasatinib 16Bortezomib 15Whole-Body Irradiation 14Vorinostat 14pegaspargase 13Cyclosporine 13Calcium Dobesilate 13Busulfan 13Antilymphocyte Serum 12tanespimycin 10Topotecan 10Stem Cell Transplantation 10Specimen Handling 10Sirolimus 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × CB-839 × Clear all
NCT02071927 2017-02-09

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Calithera Biosciences, Inc

Phase 1 Completed
43 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡